Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE) Stock Overview

Explore Maze Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

MAZE●NASDAQ
HealthcareBiotechnology
$22.39
$0.13(0.58%)
U.S. Market opens in 12h 10m

Maze Therapeutics, Inc. (MAZE)

Meyka AI Score

Z

Key Financials

Market Cap1.2B
P/E Ratio-8.16
EPS (TTM)$-2.53
ROE-0.35%
Fundamental Analysis

AI Price Forecasts

1 Month$35.67
3 Months$52.03
1 Year Target$54.65

MAZE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Maze Therapeutics, Inc. (NASDAQ: MAZE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Maze Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of MAZE on the NASDAQ shows an RSI of 25.20, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $54.65 for the NASDAQ listing.

Key metrics behind Maze Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -8.16 and a market capitalization of 1.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MAZE on the NASDAQ.

Price Performance (NASDAQ: MAZE)

1-Day Change
-0.58%
5-Day Change
-7.97%
1-Month Change
-23.92%
3-Month Change
-12.44%
6-Month Change
-53.38%
Year-to-Date (YTD) Change
-45.96%
1-Year Change
-5.41%
3-Year Change
40.38%
5-Year Change
40.38%
All-Time (Max) Change
40.38%

Contact Information

https://www.mazetx.com
650 850 5070
171 Oyster Point Blvd, South San Francisco, CA, 94080

Company Facts

1,410 Employees
IPO DateJan 31, 2025
CountryUS
Actively Trading

Frequently Asked Questions